<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514605</url>
  </required_header>
  <id_info>
    <org_study_id>2007-01</org_study_id>
    <nct_id>NCT00514605</nct_id>
  </id_info>
  <brief_title>Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection</brief_title>
  <official_title>A Study to Evaluate the Point-of-Care Use and Laboratory Investigational Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>bioLytical Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>bioLytical Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each year up to 22 million persons in the US are tested for HIV. Currently available &quot;rapid&quot;&#xD;
      tests do not provide test results for at least 30 minutes from the collection of serum and&#xD;
      plasma from the subject. Providing accurate test results in less than a minute would make it&#xD;
      easier to make timely decisions about treatment and counselling.&#xD;
&#xD;
      This study will compare results of an experimental rapid test to existing standards to&#xD;
      determine if the test can reliably and accurately diagnose HIV in less than one minute.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine if INSTI™ performed with finger-stick whole blood,&#xD;
      venous whole blood, and plasma demonstrates at least 98.0% sensitivity and specificity&#xD;
      compared to an FDA-approved HIV testing algorithm.&#xD;
&#xD;
      The study will have two parts. The first part of the study will be conducted in institutions&#xD;
      where HIV testing is routinely performed and where HIV counseling is offered [i.e. point of&#xD;
      care (POC) centers]. The second part of the study will be conducted in a central laboratory&#xD;
      that routinely conducts laboratory-based HIV testing using an FDA-licensed HIV-1 ELISA and&#xD;
      Western blot test.&#xD;
&#xD;
      Geographically diverse POCs will be selected in the USA. Approximately 15-20 POCs are&#xD;
      planned. Approximately 2,500 subjects will participate in the study including 1,500 subjects&#xD;
      with unknown HIV status and 1,000 seropositive subjects. Across these POC sites, voluntary&#xD;
      testing of 1500 subjects with unknown HIV status is planned with at least 500 of these&#xD;
      subjects being high risk. Samples will be obtained from consenting subjects in the voluntary&#xD;
      testing population including high-risk and known HIV 1 seropositive individuals.&#xD;
&#xD;
      Each subject is to receive an INSTI™ on finger-stick blood and parallel HIV testing of&#xD;
      EDTA-treated venous whole blood and plasma samples will be conducted at a central laboratory.&#xD;
&#xD;
      The results of INSTI™ will not be given to the subject. The subject will be given the results&#xD;
      of the POC HIV test only, per their standard of care procedures. Subsequent subject care&#xD;
      decisions will NOT be based on the results of INSTI™.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 20, 2007</completion_date>
  <primary_completion_date type="Actual">November 20, 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INSTI™ performed with finger-stick whole blood, venous whole blood, and plasma demonstrates at least 98.0% sensitivity and specificity compared to an FDA-approved HIV testing algorithm</measure>
    <time_frame>&lt;1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of INSTI™ results that agree between finger-stick whole blood, venous whole blood, and plasma.</measure>
    <time_frame>&lt; 1 week</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Behavioral counseling</intervention_name>
    <description>Standard-of-Care counseling at the Point-of-Care.</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIV-1 Antibody Test Kit</intervention_name>
    <description>Assay to detect HIV antibodies</description>
    <other_name>INSTI™ HIV-1 Antibody Test Kit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unknown HIV status who are undergoing voluntary testing for HIV infection in a POC&#xD;
             clinic setting or known HIV seropositive subjects willing to be re-tested.&#xD;
&#xD;
          -  Ability to give proper informed consent, or have legal parent or guardian provide&#xD;
             consent.&#xD;
&#xD;
          -  Willingness to participate in a POC standard of care HIV counseling and testing&#xD;
             program and receive POC standard of care test results&#xD;
&#xD;
          -  Willingness to provide the necessary volume of whole blood collected through venous&#xD;
             blood draw and finger stick (approximately 10 ml)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject self-report of history of multiple myeloma&#xD;
&#xD;
          -  Subject self-report of history of long-term anti-retroviral therapy with known low or&#xD;
             non-existent antibody titre (sero-inversion)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LA County STD Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Sumero, MD</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Medical</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Epidemiology, Johns Hopkins School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Development and Research Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Academy of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazzoni Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS/HIV Services Group</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Over Ministry</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <name_title>Rick Galli</name_title>
    <organization>Biolytical Laboratories</organization>
  </responsible_party>
  <keyword>HIV 1</keyword>
  <keyword>AIDS</keyword>
  <keyword>Assay</keyword>
  <keyword>Rapid Test</keyword>
  <keyword>HIV-1</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

